Inflammatory bowel disease, or IBD in short, refers to a group of disorders characterized by chronic inflammation of the gastrointestinal tract. IBD primarily includes Crohn's disease and ulcerative colitis. It is estimated that 2.4 million individuals are currently diagnosed with IBD in the U.S., with 70,000 new cases being diagnosed each year.
The company we are profiling today is Spyre Therapeutics Inc. (SYRE), a clinical-stage biotechnology company developing next generation therapeutics for people living with IBD, including ulcerative colitis and Crohn's disease.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.